Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib + Gemcitabine + Cisplatin in Advanced NSCLC
NCT00055757Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Proportion of confirmed tumor responses up to 18 weeks. Started Oct 2003; status: completed.
02
Drugs
tipifarnib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00055757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055757.